Disposition of 8752 shares by Brian Harvey of Adicet Bio at 0.9218 subject to Rule 16b-3
| ACET Stock | USD 0.67 0.02 2.90% |
Slightly above 62% of Adicet Bio's investor base is looking to short. The analysis of overall sentiment of trading Adicet Bio stock suggests that many investors are alarmed at this time. Adicet Bio's investing sentiment can be driven by a variety of factors including economic data, Adicet Bio's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Adicet Bio Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Adicet Bio Fundamental Analysis
We analyze Adicet Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adicet Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adicet Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Adicet Bio is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Adicet Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adicet Bio stock to make a market-neutral strategy. Peer analysis of Adicet Bio could also be used in its relative valuation, which is a method of valuing Adicet Bio by comparing valuation metrics with similar companies.
Peers
Adicet Bio Related Equities
| DSGN | Design Therapeutics | 1.29 |
| ||
| AAON | AAON | 2.22 |
| ||
| ADCT | ADC Therapeutics | 2.89 |
| ||
| ACTG | Acacia Research | 3.11 |
| ||
| ABCB | Ameris Bancorp | 3.57 |
| ||
| ACIW | ACI Worldwide | 4.28 |
| ||
| ALXO | Alx Oncology | 8.77 |
|
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.